SCHEMBL3051656

SCHEMBL3051656

Cc1ccc(Nc2nc3nonc3nc2NN=Cc2ccc(-c3ccc(Br)cc3)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.49
MEN1 O00255 9/20 0.48
KMT2A Q03164 9/20 0.48
POLB P06746 7/20 0.48
GAA P10253 5/20 0.48
MAPT P10636 12/20 0.48
KDM4E B2RXH2 8/20 0.48
ALDH1A1 P00352 6/20 0.48
RAB9A P51151 7/20 0.46
NPSR1 Q6W5P4 4/20 0.46
NPC1 O15118 4/20 0.46
HPGD P15428 2/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RECQL P46063 1/20 0.43
HTT P42858 3/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051653 1.00 BIRC5 (0.49) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6437056 0.88 BIRC5 (0.55) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6437058 0.88 BIRC5 (0.55) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6420773 0.82 BIRC5 (0.57) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6416003 0.81 MEN1 (0.61) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6435673 0.80 MEN1 (0.48) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6505849 0.80 BIRC5 (0.53) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6505842 0.80 BIRC5 (0.53) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6419740 0.77 BIRC5 (0.57) BIRC5MEN1KMT2APOLBGAA
SCHEMBL6419733 0.77 BIRC5 (0.57) BIRC5MEN1KMT2APOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US claimed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US claimed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP claimed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US disclosed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US disclosed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP disclosed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 BIRC5 13/4885MEN1 35/4885KMT2A 3960/4885
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, RB1, CA5A BIRC5 21/4885MEN1 37/4885KMT2A 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.